Literature DB >> 35178660

Suppressive effects of processed aconite root on dexamethasone-induced muscle ring finger protein-1 expression and its active ingredients.

Taishi Kondo1, Tomoaki Ishida1, Ke Ye1, Marin Muraguchi1, Yohei Tanimura1, Masato Yoshida1, Kan'ichiro Ishiuchi1, Tomoki Abe2, Takeshi Nikawa3, Keisuke Hagihara4, Hidetoshi Hayashi5, Toshiaki Makino6.   

Abstract

Processed aconite root (PA), the tuberous root of Aconitum carmichaelii prepared by autoclaving, is a crude drug used in Japanese traditional Kampo medicine and traditional Chinese medicine for the symptoms of kidney deficiency, that is related to the muscle atrophy in modern medicine. The objective of the present study is to evaluate the effectiveness of PA on muscle atrophy and to find its active ingredients using dexamethasone-induced muscle ring finger protein-1 (MuRF1) mRNA expression in murine myoblast C2C12 cells. Dexamethasone-induced MuRF1 expression was significantly suppressed by methanol-soluble part of boiling water extract of PA in a concentration-dependent manner with its IC50 value of 1.5 mg/ml. By the activity-guided fractionations of PA extract using the partition between organic solvents and its aqueous solution, the activity of PA did not transfer into the fraction containing aconitine-type diterpenoid alkaloids but into BuOH layer. Then, we found higenamine and salsolinol as the active ingredients in PA. Higenamine and salsolinol significantly suppressed dexamethasone-induced MuRF1 expression, and their IC50 values were 0.49 and 50 µM, respectively. The contents of higenamine and salsolinol in the decoctions of commercially available fourteen PA products are 0.12 and 14 µg/ml as the average values, and varied with the coefficient of variation (CV) values of 97 and 63%, respectively. Higenamine also significantly suppressed dexamethasone-induced mRNA expressions of muscle atrophy F-box protein (MAFbx)/atrogin1, casitas B-lineage lymphoma-b (Cbl-b), troponin, branched-chain amino acid aminotransferase 2 (BCAT2), and Bcl-2 binding and pro-apoptotic protein3 (Bnip3). Although the quality control of PA is regulated by the contents of diterpene alkaloids, salsolinol and higenamine can be used as the marker compounds to certificate the pharmacological activities of PA.
© 2022. The Author(s) under exclusive licence to The Japanese Society of Pharmacognosy.

Entities:  

Keywords:  Higenamine; Muscle ring finger protein-1; Muscular atrophy; Processed aconite root; Salsolinol

Mesh:

Substances:

Year:  2022        PMID: 35178660     DOI: 10.1007/s11418-022-01606-5

Source DB:  PubMed          Journal:  J Nat Med        ISSN: 1340-3443            Impact factor:   2.343


  27 in total

Review 1.  Ubiquitin-Proteasome Pathway and Muscle Atrophy.

Authors:  Rania Khalil
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

Review 2.  Potential application of the Kampo medicine goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy.

Authors:  Marco Cascella; Maria Rosaria Muzio
Journal:  J Integr Med       Date:  2017-03

3.  Go-sha-jinki-Gan (GJG), a traditional Japanese herbal medicine, protects against sarcopenia in senescence-accelerated mice.

Authors:  Yuki Kishida; Syota Kagawa; Junsuke Arimitsu; Miho Nakanishi; Noriko Sakashita; Shizue Otsuka; Hideki Yoshikawa; Keisuke Hagihara
Journal:  Phytomedicine       Date:  2014-11-20       Impact factor: 5.340

4.  Neoline, an active ingredient of the processed aconite root in Goshajinkigan formulation, targets Nav1.7 to ameliorate mechanical hyperalgesia in diabetic mice.

Authors:  Yoshihiko Nakatani; Kanako Negoro; Miki Yamauchi; Maki Katasho; Kei-Ichiro Ishikura; Anna Iwaki; Kazuyo Tsukada; Marina Yamaguchi; Arata Uehara; Masato Yoshida; Kan'ichiro Ishiuchi; Toshiaki Makino; Masaki Kitajima; Masahiro Ohsawa; Taku Amano
Journal:  J Ethnopharmacol       Date:  2020-05-18       Impact factor: 4.360

5.  Goshajinkigan for Low Back Pain: An Observational Study.

Authors:  Takuya Hamaguchi; Tetsuhiro Yoshino; Yuko Horiba; Kenji Watanabe
Journal:  J Altern Complement Med       Date:  2016-12-19       Impact factor: 2.579

6.  Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia.

Authors:  Liang-Kung Chen; Li-Kuo Liu; Jean Woo; Prasert Assantachai; Tung-Wai Auyeung; Kamaruzzaman Shahrul Bahyah; Ming-Yueh Chou; Liang-Yu Chen; Pi-Shan Hsu; Orapitchaya Krairit; Jenny S W Lee; Wei-Ju Lee; Yunhwan Lee; Chih-Kuang Liang; Panita Limpawattana; Chu-Sheng Lin; Li-Ning Peng; Shosuke Satake; Takao Suzuki; Chang Won Won; Chih-Hsing Wu; Si-Nan Wu; Teimei Zhang; Ping Zeng; Masahiro Akishita; Hidenori Arai
Journal:  J Am Med Dir Assoc       Date:  2014-02       Impact factor: 4.669

7.  Targeted ablation of the cellular inhibitor of apoptosis 1 (cIAP1) attenuates denervation-induced skeletal muscle atrophy.

Authors:  Neena Lala-Tabbert; Rim Lejmi-Mrad; Kristen Timusk; Marina Fukano; Janelle Holbrook; Martine St-Jean; Eric C LaCasse; Robert G Korneluk
Journal:  Skelet Muscle       Date:  2019-05-24       Impact factor: 4.912

8.  Goshajinkigan, a Traditional Japanese Medicine, Suppresses Voltage-Gated Sodium Channel Nav1.4 Currents in C2C12 Cells.

Authors:  Ryota Imai; Shoichiro Horita; Yuko Ono; Keisuke Hagihara; Masaru Shimizu; Yuko Maejima; Kenju Shimomura
Journal:  Biores Open Access       Date:  2020-04-27

9.  Go-sha-jinki-Gan (GJG) ameliorates allodynia in chronic constriction injury-model mice via suppression of TNF-α expression in the spinal cord.

Authors:  Miho Nakanishi; Aya Nakae; Yuki Kishida; Kousuke Baba; Noriko Sakashita; Masahiko Shibata; Hideki Yoshikawa; Keisuke Hagihara
Journal:  Mol Pain       Date:  2016-06-13       Impact factor: 3.395

10.  Corrigendum to "Long-Term Effects of Goshajinkigan in Prevention of Diabetic Complications: A Randomized Open-Labeled Clinical Trial".

Authors:  K Watanabe; A Shimada; K Miyaki; A Hirakata; K Matsuoka; K Omae; I Takei
Journal:  Evid Based Complement Alternat Med       Date:  2016-07-19       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.